De-Risking Drug Development Through Asymmetric Synthesis

From a process chemistry perspective, prioritizing asymmetric synthesis fosters efficient, cost-effective pharmaceutical development. While chromatography serves niche needs, the long-term advantages of asymmetric routes, including scalable purity, reduced waste, and lower COGs, outweigh initial investments, especially for complex chiral molecules. Engaging experts like Wilmington early, pre-IND, maximizes value, reduces costs, and drives innovation. Pharma clients should evaluate asymmetric options first to capitalize on these benefits, acknowledging hybrids where needed for ultimate success.

Wilmington PharmaTech supports clients in evaluating asymmetric options early, helping teams establish scalable stereo-controlled routes before late-stage constraints emerge. Pre-IND stereochemical strategy assessments can provide clarity on the most robust path forward for complex chiral APIs.